BRIEF published on 06/16/2026 at 21:21, 2 months 28 days ago Medincell: Key Results and Initiatives for 2025-2026 Innovation Treasury R&D Royalties Medincell
PRESS RELEASE published on 06/16/2026 at 21:16, 2 months 28 days ago Informations privilégiées / Communiqué sur comptes, résultats Medincell publie ses résultats financiers annuels consolidés pour l'exercice 2025-2026, mettant en avant la solidité opérationnelle et la transition vers un modèle reposant sur l'innovation et les revenus récurrents Résultats Financiers Innovation Revenus Récurrents Medincell Exercice 2025-2026
BRIEF published on 05/21/2026 at 19:29, 3 months 24 days ago L'EMA accepte la demande de Teva pour un traitement de la schizophrénie à action prolongée Traitement De La Schizophrénie Teva Pharmaceuticals Approbation De L'EMA Olanzapine Injectable Formule À Action Prolongée
BRIEF published on 05/21/2026 at 19:29, 3 months 24 days ago EMA Accepts Teva's Application for Long-Acting Schizophrenia Treatment Schizophrenia Treatment Teva Pharmaceuticals EMA Approval Olanzapine Injectable Long-acting Formulation
PRESS RELEASE published on 05/21/2026 at 19:24, 3 months 24 days ago Informations privilégiées / Autres communiqués L'EMA accepte le dossier de demande de mise sur le marché de l'Olanzapine LAI par Teva pour le traitement de la schizophrénie. Technologie de libération prolongée SteadyTeq(TM) utilisée Schizophrénie Teva EMA Olanzapine LAI SteadyTeq
PRESS RELEASE published on 05/21/2026 at 19:24, 3 months 24 days ago Inside Information / Other news releases European Medicines Agency accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable to treat schizophrenia in adults. Teva and Medincell announce EMA acceptance for innovative treatment option Schizophrenia Medincell Olanzapine Teva EMA
BRIEF published on 04/29/2026 at 13:44, 4 months 16 days ago Croissance impressionnante des ventes de UZEDY® au T1 2026 Schizophrénie Medincell Teva Pharmaceuticals UZEDY® Ventes T1 2026
BRIEF published on 04/29/2026 at 13:44, 4 months 16 days ago UZEDY® Q1 2026 Sales Surge by 62% FDA Approvals Olanzapine LAI UZEDY® Sales Teva Partnership Medincell Growth
BRIEF published on 04/29/2026 at 13:44, 4 months 16 days ago Impressive sales growth for UZEDY® in Q1 2026 Schizophrenia Medincell Teva Pharmaceuticals UZEDY® Q1 2026 Sales
BRIEF published on 04/29/2026 at 13:44, 4 months 16 days ago Les ventes d'UZEDY® au premier trimestre 2026 devraient bondir de 62 %. Olanzapine LAI Ventes UZEDY® Partenariat Avec Teva Approbations De La FDA Croissance De Medincell
Published on 09/15/2026 at 15:45, 22 minutes ago Galaxy Ventures Inc. Announces Major Milestones for Qualifying Transaction: TruSilver Completes $2.5 Million Financing and Appoints Former IAMGOLD Chief Geologist Matt Rees as Director and Vice-President of Exploration
Published on 09/15/2026 at 15:35, 32 minutes ago Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
Published on 09/15/2026 at 15:25, 42 minutes ago Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
Published on 09/15/2026 at 15:20, 47 minutes ago MicroVision Showcases Expanding Perception Portfolio at IAA Transportation 2026
Published on 09/15/2026 at 15:00, 1 hour 7 minutes ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 09/15/2026 at 15:20, 47 minutes ago Circana Enhances Unify+ with AI-Powered Analysis Builder for Faster, More Intuitive Reporting
Published on 09/15/2026 at 07:00, 9 hours 7 minutes ago AXA announces its 2027-2029 strategy and financial targets
Published on 09/15/2026 at 07:00, 9 hours 7 minutes ago AXA annonce son plan stratégique 2027-2029 ainsi que ses objectifs financiers
Published on 09/14/2026 at 18:21, 21 hours 46 minutes ago Reporting on share buyback transactions carried out between September 7 and September 10, 2026
Published on 09/14/2026 at 18:21, 21 hours 46 minutes ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 7 et le 10 septembre 2026
Published on 09/14/2026 at 18:00, 22 hours 7 minutes ago Mint franchit une nouvelle étape de sa transformation BtoB : deux signatures majeures viennent conforter une stratégie de croissance récurrente en accélération
